Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-04802367是 GSK-3高选择性抑制剂,对 GSK-3β酶的 IC50为 2.1 nM。它抑制两种 GSK-3 亚型(GSK-3α和GSK-3β)效果差不多,IC50值分别为 10.0 和 9.0 nM。它具有理想的中枢神经系统特性和效力。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 841 | 现货 | ||
5 mg | ¥ 2,160 | 现货 | ||
10 mg | ¥ 3,490 | 现货 | ||
25 mg | ¥ 5,690 | 现货 | ||
50 mg | ¥ 7,950 | 现货 | ||
100 mg | ¥ 10,700 | 现货 | ||
500 mg | ¥ 21,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,370 | 现货 |
产品描述 | PF-04802367 is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. It shows desirable central nervous system (CNS) properties and potency. It is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively. |
靶点活性 | GSK-3α:10 nM (IC50), GSK-3β:9 nM (IC50) |
体外活性 |
PF-04802367 (PF-367) is efficient at inhibiting GSK-3β enzymatic activity in vitro with ligand and lipophilic efficiency scores of 0.46 and 7.0, respectively[1]. PF-367 has reasonable in vitro stability in human hepatic microsomes (t1/2=78.7 min), has excellent passive permeability[1]. In a stable inducible CHO cell line over-expressing GSK-3β and its substrate tau, PF-367 inhibited phosphorylation of tau with an IC50 of 466 nM[1]. PF-367 has good cell viability (IC50 of 117 μM in THLE cytotoxicity assays) and an IC50 >100 μM in a hERG screening assay[1]. PF-367 shows significant right shifts against β-catenin translocation in HeLa cells with EC50 of 6.2 μM, gene transcription in U20S cells with EC50 of 20.6 μM, and cell proliferation in HeLa cells as evaluated by Ki-67 incorporation with EC50 of 9.0 μM[1]. |
体内活性 |
PF-04802367 (PF-367) a potent GSK-3 inhibitor with exceptional kinome selectivity that modulates phosphorylated tau levels in vivo. Inhibition of phosphorylation of tau in brain by PF-367 (A single subcutaneous of 1, 3.2, 10, 32 or 50 mg/kg) is dose-dependent[1]. PF-04802367 (PF-367), a potent type-I dual GSK-3α/β inhibitor, showing promising absorption; distribution, metabolism and elimination (ADME) properties combined with robust CNS/peripheral p-Tau and muscle phosphorylated glycogen synthase (pGS) inhibition in vivo[2]. |
分子量 | 361.78 |
分子式 | C16H16ClN5O3 |
CAS No. | 1962178-27-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (276.41 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7641 mL | 13.8206 mL | 27.6411 mL | 69.1028 mL |
5 mM | 0.5528 mL | 2.7641 mL | 5.5282 mL | 13.8206 mL | |
10 mM | 0.2764 mL | 1.3821 mL | 2.7641 mL | 6.9103 mL | |
20 mM | 0.1382 mL | 0.691 mL | 1.3821 mL | 3.4551 mL | |
50 mM | 0.0553 mL | 0.2764 mL | 0.5528 mL | 1.3821 mL | |
100 mM | 0.0276 mL | 0.1382 mL | 0.2764 mL | 0.691 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-04802367 1962178-27-3 PI3K/Akt/mTOR signaling Stem Cells GSK-3 PF367 PF 367 protein PF 04802367 disease Alzheimer PF-367 Glycogen synthase kinase-3 kinase-3 synthase Inhibitor phosphorylation neurology neurodegenerative tau Glycogen synthase kinase 3 inhibit Glycogen PF04802367 inhibitor